96. クローン病
[臨床試験数:2,209,薬物数:1,276(DrugBank:240),標的遺伝子数:166,標的パスウェイ数:210

Searched query = "Crohn disease", "Terminal ileitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03773237
(ClinicalTrials.gov)
December 31, 201812/11/2018Intralipid Versus SMOFlipid in HPN PatientsRandomized Prospective Trial Comparing Intralipid Versus SMOFlipid in New HPN Patients.Short Bowel Syndrome;Intestinal Fistula;Crohn Disease;Intestinal ObstructionDietary Supplement: SMOFLipid;Dietary Supplement: IntralipidMayo ClinicNULLRecruiting18 Years75 YearsAll100N/AUnited States
2NCT02349594
(ClinicalTrials.gov)
January 201416/1/2015Immune Modulation by Parenteral Fish Oil in Patients With Crohn's DiseaseModulation of Immune Function by Parenteral Fish Oil in Patients With Crohn's Disease and High Inherent Tumor Necrosis Factor-alpha Production: a Randomized, Single Blinded, Cross-over StudyCrohn DiseaseDrug: Omegaven 10%;Drug: Intralipid 20%Radboud UniversityNULLCompleted18 Years70 YearsBoth6Phase 4Netherlands
3EUCTR2013-001212-30-NL
(EUCTR)
04/07/201318/06/2013Immune modulation by parenteral Fish oil in patients with Crohn’s diseaseModulation of immune function by parenteral fish oil in patients with Crohn’s disease and high inherent Tumor Necrosis Factor-alfa production, a randomized, single blinded, cross-over study Crohn's disease;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]Trade Name: Omegaven
Trade Name: Intralipid 10%
NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Netherlands